Table 1.

Comparison of baseline characteristics of patients in the convalescent plasma and the control group.

	Convalescent Plasma Group (n = 59)	Control Group (n = 59)	p-Value
Age, median (IQR)	59 (18.0)	59 (20)	0.893
<60 years %	45.8	50.8
≥60 years %	55.2	49.2
Gender, %			0.564
Female	32.2	37.3
Male	67.8	62.7
Comorbidities, %	61.0	62.7	0.393
Diabetes	19.3	28.3	0.269
Arterial hypertension	29.8	37.7	0.382
Coronary artery disease	7.0	13.2	0.282
Heart failure	3.5	9.4	0.205
Pulmonary disease	14.0	9.4	0.457
Renal impairment	8.8	11.3	0.276
Solid tumor	1.8	7.5	0.658
Hematological malignancy	3.5	1.9	0.603
Symptoms, %
Fever	98.2	96.6	0.571
Myalgia	8.8	10.3	0.775
Cough	56.1	48.3	0.401
Dyspnea	36.8	53.4	0.08
Loss of taste	8.8	3.4	0.235
Anosmia	5.3	5.2	0.983
Diarrhea	19.3	19.0	0.964
Baseline laboratory parameters, median (IQR)
Lymphocytes, (109/L, NR: 1.1–4.0)	1.17 (0.7)	1.02 (0.6)	0.207
Platelets, (109/L, NR: 130–400)	196 (101.5)	197 (75.3)	0.721
CRP, (mg/L, NR: 0.00–6.00)	47 (50.3)	44.8 (71.9)	0.772
Fibrinogen, (mg/dL, NR: 200–400)	485 (173)	477 (253.9)	0.631
LDH, (U/L, NR: 135–225)	315 (167.8)	277 (127.3)	0.165
Ferritin, (ng/mL, NR: 13–150)	597 (451.5)	474 (167.9)	0.443
Intereukin-6, (pg/mL, NR: <7)	30.5 (43.6)
SARS-CoV-2 PCR CT value	26.8 (6.9)	27.5 (9.3)	0.700
Percentage of infiltrates at baseline CT, %			0.117
<25	29.1	39.6
25–50	38.2	43.8
50–75	25.5	8.3
≥75%	7.3	8.3
Concomitant dexamethasone, %	59.3	49.2	0.270
Baseline SOFA score	5 (4)	4 (4)	0.295
Time from first symptom to diagnosis, median (IQR)	3 (4]	4 (3)	0.265
Time from first symptom to CP infusion, median (IQR)	7 (4)
Time from diagnosis to CP infusion, median (IQR)	3 (3)